Grace Juyun Kim1, Soo Youn Lee2, Ji Hye Park2, Brian Y Ryu2, Ju Han Kim3,4. 1. Seoul National University Biomedical Informatics (SNUBI), 28 Yongon-dong, Chongno-gu, Seoul, 110799, South Korea. 2. Interdisciplinary Program in Bioinformatics, Seoul National University College of Natural Sciences, 28 Yongon-dong, Chongno-gu, Seoul, 110799, South Korea. 3. Seoul National University Biomedical Informatics (SNUBI), 28 Yongon-dong, Chongno-gu, Seoul, 110799, South Korea. juhan@snu.ac.kr. 4. Division of Biomedical Informatics, Systems Biomedical Informatics National Core Research Center (SBI-NCRC), Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110799, South Korea. juhan@snu.ac.kr.
Abstract
INTRODUCTION: Preemptive and multi-variant genotyping is suggested to improve the safety of patient drug therapy. The number of South Koreans who would benefit from this approach is unknown. OBJECTIVE: We aimed to quantify the number of patients who may experience serious adverse drug events (ADEs) due to high-risk pharmacogenetic variants and who may benefit from preemptive genotyping. METHODS: The health claims dataset of the Korean Health Insurance Review and Assessment service for 3 % of the South Korean population for year 2011 was used to calculate the number of patients exposed to 84 drugs covered by National Health Insurance with pharmacogenomic biomarkers. The product of ADE risk-conferring genotype prevalence, ADE prevalence rates, and genotype effect sizes in South Koreans or East Asians derived from published literature and the 1000 Genomes Project, and the drug exposure data were solved to estimate the number of South Koreans in whom preemptive genotyping may prevent serious ADEs. RESULTS: Among 1,341,077 patients in the dataset with prescriptions, 47.4 % were prescribed a drug whose response was affected by genetic variants and 31.9 % were prescribed at least one drug with serious ADEs modulated by these variants. Without genetic testing, the number of South Korean patients predicted to experience serious ADEs due to their higher ADE risk genotypes was estimated at 729. Extrapolating this to the total South Korean population indicated that approximately 24,300 patients in 2011 might have benefitted from preemptive genotyping. CONCLUSIONS: This study quantified the number of South Korean patients predicted to have serious ADEs and demonstrated the need for preemptive genotyping to assist safer drug therapy in South Korea.
INTRODUCTION: Preemptive and multi-variant genotyping is suggested to improve the safety of patient drug therapy. The number of South Koreans who would benefit from this approach is unknown. OBJECTIVE: We aimed to quantify the number of patients who may experience serious adverse drug events (ADEs) due to high-risk pharmacogenetic variants and who may benefit from preemptive genotyping. METHODS: The health claims dataset of the Korean Health Insurance Review and Assessment service for 3 % of the South Korean population for year 2011 was used to calculate the number of patients exposed to 84 drugs covered by National Health Insurance with pharmacogenomic biomarkers. The product of ADE risk-conferring genotype prevalence, ADE prevalence rates, and genotype effect sizes in South Koreans or East Asians derived from published literature and the 1000 Genomes Project, and the drug exposure data were solved to estimate the number of South Koreans in whom preemptive genotyping may prevent serious ADEs. RESULTS: Among 1,341,077 patients in the dataset with prescriptions, 47.4 % were prescribed a drug whose response was affected by genetic variants and 31.9 % were prescribed at least one drug with serious ADEs modulated by these variants. Without genetic testing, the number of South Korean patients predicted to experience serious ADEs due to their higher ADE risk genotypes was estimated at 729. Extrapolating this to the total South Korean population indicated that approximately 24,300 patients in 2011 might have benefitted from preemptive genotyping. CONCLUSIONS: This study quantified the number of South Korean patients predicted to have serious ADEs and demonstrated the need for preemptive genotyping to assist safer drug therapy in South Korea.
Authors: James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling Journal: Am J Med Genet C Semin Med Genet Date: 2014-03-11 Impact factor: 3.908
Authors: In Hae Park; Jungsil Ro; Sohee Park; Hyeong-Seok Lim; Keun Seok Lee; Han Sung Kang; So-Youn Jung; Seeyeon Lee Journal: Breast Cancer Res Treat Date: 2011-03-25 Impact factor: 4.872
Authors: S L Van Driest; Y Shi; E A Bowton; J S Schildcrout; J F Peterson; J Pulley; J C Denny; D M Roden Journal: Clin Pharmacol Ther Date: 2013-11-19 Impact factor: 6.875
Authors: Melanie M Hagleitner; Marieke J H Coenen; Ana Patino-Garcia; Eveline S J M de Bont; Anna Gonzalez-Neira; Hanneke I Vos; Frank N van Leeuwen; Hans Gelderblom; Peter M Hoogerbrugge; Henk-Jan Guchelaar; Maroeska W M Te Loo Journal: PLoS One Date: 2014-12-31 Impact factor: 3.240
Authors: Zul Premji; Rich E Umeh; Seth Owusu-Agyei; Fabian Esamai; Emmanuel U Ezedinachi; Stephen Oguche; Steffen Borrmann; Akintunde Sowunmi; Stephan Duparc; Paula L Kirby; Allan Pamba; Lynda Kellam; Robert Guiguemdé; Brian Greenwood; Stephen A Ward; Peter A Winstanley Journal: PLoS One Date: 2009-08-19 Impact factor: 3.240
Authors: J B Singer; Y Shou; F Giles; H M Kantarjian; Y Hsu; A S Robeva; P Rae; A Weitzman; J M Meyer; M Dugan; O G Ottmann Journal: Leukemia Date: 2007-07-05 Impact factor: 11.528
Authors: Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle Journal: Annu Rev Genomics Hum Genet Date: 2022-05-10 Impact factor: 9.340
Authors: Kye Hwa Lee; Dong Yoon Kang; Hyun Hwa Kim; Yi Jun Kim; Hyo Jung Kim; Ju Han Kim; Eun Young Song; James Yun; Hye-Ryun Kang Journal: Clin Transl Allergy Date: 2022-01-14 Impact factor: 5.871
Authors: Immaculate M Langmia; Katja S Just; Sabrina Yamoune; Jürgen Brockmöller; Collen Masimirembwa; Julia C Stingl Journal: Front Genet Date: 2021-07-12 Impact factor: 4.599